Case reports in oncology · 2026
Uncommon Complication of Transarterial Chemoembolization with Doxorubicin: A Case of Post-TACE Neutropenia in Hepatocellular Carcinoma.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hajmusa Muhammed, Obaid Koutaibah Rida, Abdalhadi Ahmed M, Mohamed Sittna, Kanbour Aladdin
Аннотация
INTRODUCTION: Transarterial chemoembolization (TACE) using doxorubicin is an established treatment option for unresectable hepatocellular carcinoma (HCC) in cirrhotic patients. In this case report, we describe a rare occurrence of delayed febrile neutropenia following conventional TACE (C-TACE) with doxorubicin. This complication, while recognized with systemic doxorubicin, is rarely documented in the context of C-TACE.
CASE PRESENTATION: We present a 53-year-old Bangladeshi man with hepatitis B-related HCC who developed febrile neutropenia 2 weeks following C-TACE with doxorubicin. Indeed, previous C-TACE procedures had also resulted in similar neutropenic episodes, which pointed to the association of C-TACE with doxorubicin and neutropenia.
CONCLUSION: The case brings attention and vigilance to the monitoring for neutropenia in patients receiving C-TACE with doxorubicin, an association rarely currently documented in the literature. Further studies are needed to assess its prevalence and identify risk factors and management strategies for this complication.
CASE PRESENTATION: We present a 53-year-old Bangladeshi man with hepatitis B-related HCC who developed febrile neutropenia 2 weeks following C-TACE with doxorubicin. Indeed, previous C-TACE procedures had also resulted in similar neutropenic episodes, which pointed to the association of C-TACE with doxorubicin and neutropenia.
CONCLUSION: The case brings attention and vigilance to the monitoring for neutropenia in patients receiving C-TACE with doxorubicin, an association rarely currently documented in the literature. Further studies are needed to assess its prevalence and identify risk factors and management strategies for this complication.